newsfilter
← Latest News
Business Wire·

Humanigen Reports Year-End 2021 Financial Results

Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab, today reported financial results for the